Skip to main content
SpringerLink
Log in

Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not?

  • Commentary
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):299S–339S

    Article  CAS  Google Scholar 

  2. Baumgartner H, Falk V, Bax JJ, et al. ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.

    Article  Google Scholar 

  3. Hindricks G, Potpara T, Dagres N, et al. ESC scientific document group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498.

    Article  Google Scholar 

  4. Fawzy AM, Lip GYH. Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. Expert Opin Drug Metab Toxicol. 2019;15:381–98.

    Article  CAS  Google Scholar 

  5. Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385:2288–95.

    Article  CAS  Google Scholar 

  6. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76:776–86.

    Article  CAS  Google Scholar 

  7. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70:703–12.

    Article  CAS  Google Scholar 

  8. Reilly PA, Lehr T, Haertter S, et al., RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321–8.

    Article  CAS  Google Scholar 

  9. Beasley BN, Unger EF, Temple R. Anticoagulant options—why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364:1788–90.

    Article  CAS  Google Scholar 

  10. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.

    Article  CAS  Google Scholar 

  11. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–34.

    Article  CAS  Google Scholar 

  12. Lip GYH, Collet JP, Haude M, et al. ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019;21:192–3.

    Article  Google Scholar 

  13. Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

    Article  CAS  Google Scholar 

  14. Steinberg BA, Shrader P, Pieper K, et al. Frequency and outcomes of reduced dose non–vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc. 2018;7(4):7633.

    Article  Google Scholar 

  15. Bo M, Corsini A, Brunetti E, et al. Off-label use of reduced dose direct oral factor Xa-inhibitors in subjects with atrial fibrillation: a review of clinical evidence. Eur Heart J Cardiovasc Pharmacother. 2020. https://doi.org/10.1093/ehjcvp/pvaa103.

    Article  Google Scholar 

  16. Atar D, Grundvold I. On-label reduced doses of non-vitamin K anticoagulants prove safe and efficient: yet how to ensure the correct dose for the right patient? Eur Heart J. 2019;40:1501–3.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Cardiovascular Diseases-AUSL Romagna, Ospedale S. Maria delle Croci, Viale Randi 5, IT-48121, Ravenna, Italy

    Andrea Rubboli

  2. Department of Cardiology, Oslo University Hospital Ullevål, and Institute of Clinical Sciences, University of Oslo, Kirkeveien 166, NO-0407, Oslo, Norway

    Dan Atar

Authors
  1. Andrea Rubboli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dan Atar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Rubboli.

Ethics declarations

Funding

This research received no external funding.

Conflict of Interest

Andrea Rubboli declares lecture fees and/or consulting fees from Bayer, Boehringer Ingelheim, Daiichi Sankyo, and BMS-Pfizer. Dan Atar declares honoraria from Bayer, BMS-Pfizer, Boehringer-Ingelheim, and MSD, and research funding to the institution from Medtronic, BMS-Pfizer, Bayer, and Roche Diagnostics, all outside the submitted work.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Code availability

Not applicable.

Author Contributions

Conceptualization: AR and DA. Writing the original draft: AR. Review and editing: DA. Both authors have read and agreed to the published version of the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rubboli, A., Atar, D. Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not?. Am J Cardiovasc Drugs 22, 113–115 (2022). https://doi.org/10.1007/s40256-021-00488-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-021-00488-4

Search

Navigation